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Objective: Percutaneous driveline infection continues to detract from both quality
and length of life in patients with a left ventricular assist device. We have pursued
an alternative route by using a skull-mounted percutaneous pedestal similar to
cochlear implant technology. We have now used this method in patients implanted
with the Jarvik 2000 heart (Jarvik Heart, Inc, New York, NY) as destination therapy
for end-stage (New York Heart Association class IV) heart failure.
Methods: Four men with cardiomyopathy aged 61 to 72 years received the Jarvik
2000 heart with postauricular power delivery for permanent mechanical circulatory
support. The power cable was brought through the second posterior intercostal space
and routed through the neck to a percutaneous titanium implant screwed to the skull.
This joins with the cable to the external controller and battery.
Results: In 3 patients the pedestal healed well and remained free from infection up
to 1 year. The system was user friendly, and the whole external apparatus is
exchangeable. The second patient had a subdural hematoma. This caused us to
improve the preparation and modify the implant procedure.
Conclusion: For widespread use, permanent implantable circulatory support requires
a reliable, user-friendly device with freedom from powerline infection. Our early
experience with the Jarvik 2000 heart suggests that rigid fixation and the vascularity
of scalp skin promote healing and reduce the risk of driveline infection.
Percutaneous driveline infection continues to detract from both qualityand length of life in patients undergoing placement of a left ventric-ular assist device (LVAD).1,2 Now that implantable axial flow andcentrifugal blood pumps provide the prospect for permanent mechan-ical circulatory support, it is important to minimize the infection risk.Transcutaneous energy transfer with induction coils is an emerging
option but requires a substantial increase in the implantable components attached to
the blood pump.3 We have pursued an alternative route by using a skull-mounted
percutaneous pedestal similar to cochlear implant technology (Figure 1).4 In labo-
ratory testing this innovation provided long-term freedom from infection through
rigid fixation, absence of subcutaneous fat, and efficient healing of highly vascular
scalp skin.5 We have now applied this technology in patients implanted with the
Jarvik 2000 heart (Jarvik Heart, Inc, New York, NY) as destination therapy for
end-stage heart failure.6 This article describes our learning curve and the pitfalls and
advantages of the procedure.
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Patients and Methods
Four male patients aged 61 to 72 years with end-stage (New York
Heart Association class IV) dilated cardiomyopathy have received
the Jarvik 2000 heart with postauricular percutaneous power de-
livery in a limited clinical trial of permanent implantable circula-
tory support. The trial was approved by the Medical Device
Agency (United Kingdom) and the ethics committees of the Ox-
ford Radcliffe Hospital Trust and The Heart Hospital, London. It
is now 1 year since implantation in the first patient.
Device and Power System
The Jarvik 2000 heart is implanted into the apex of the failing left
ventricle, from which a 16-mm impervious Dacron graft conveys
blood to the descending thoracic aorta (Figure 1).6 The loosely
braided flexible power cable is composed of a bundle of 9 indi-
vidually insulated pacemaker-type leads, which are extrusion in-
sulated with polycarbonate polyurethane. The internal cable (Fig-
ure 2) terminates in a connector within the percutaneous titanium
pedestal (Figure 3). The external power cable, which can be
replaced in the event of damage, connects from the skull-mounted
pedestal to the belt-worn control system, which in turn is con-
nected to the battery (Figure 4). The cable uses a special connector
that plugs directly into the skull-mounted pedestal and is keyed so
that it cannot be connected improperly. The pump is controlled by
the external all-analogue control system in which the motor pump
speed is set manually and maintained at the set level by a pulse
width, modulated, speed-control circuit. The control unit incorpo-
rates a watt meter, which displays power use and alarm functions
for the pump under speed, low battery reserve, or circuit failure.
The belt-worn lithium ion (Li-ion) battery provides more than 8
hours of support at nominal flows of 3 to 4 L/min under normo-
tensive conditions. At higher flow or pressure, the belt-worn packs
discharge faster. The controller and battery system weighs only 1
kg.
Preparation for the Postauricular Pedestal
A computed tomographic (CT) scan of the skull is obtained,
followed by a 3-dimensional reconstruction to measure skull thick-
ness in the parietal area. This is variable (usually between 5 and 7
mm), and it is important that the screws do not penetrate the inner
table. Two days before the operation, the hair is cut short, and the
postauricular aspect of the scalp is shaved on the left side. The site
of the pedestal and exit site from the chest are identified and
marked with an indelible pen, with the patient in the sitting
position. The site of exit from the chest is one handsbreadth from
the midline and 2 cm above the top of the scapula in the sitting
position. The incision passes downward into the second posterior
intercostal space without danger of damaging either blood vessels
or nerves.
The pedestal is attached to the parietal bone about 5 cm behind
and slightly above the ear (Figure 2). A relatively flat area of skull
is chosen, taking care to avoid the mastoid air cells, the mastoid
emissary vein, or the lateral or sigmoid sinus. This part of the
cranium behind the ear lies within the sphere of natural awareness
and avoids trauma to the connector.
For the first patient, we used 3 separate neck incisions passing
across the midline to zigzag the cable for tension relief (Figure 5).
We now consider the zigzag to be unnecessary and use one
incision over the trapezius muscle on the posterior aspect of the
neck to provide a gentle curve between the thoracic exit and the
skull pedestal.
Surgical Procedure
The patients were brought to the intensive care unit on the evening
before the operation, where a continuous cardiac output monitor-
ing system and arterial line were inserted. An infusion of the
inodilator milrinone was started. The following morning, after
induction of anesthesia, a left-sided double-lumen endotracheal
tube was inserted, and a transesophageal echocardiography probe
was deployed. The patient was positioned in the lateral position,
providing access to the scalp, neck, left chest, and left femoral
vessels. Detailed hemodynamic control was maintained with a
combination of nitric oxide gas to reduce pulmonary arterial pres-
sure and glyceryl trinitrin, esmolol, adrenalin, and dopamine infu-
sions. We aim to complete the implantation of the power-delivery
system before heparinization. This requires about 1 hour, with the
patient in the left lateral position before beginning partial cardio-
pulmonary bypass.
The operation began with simultaneous exposure of the parietal
bone and femoral vessels by different teams. In the event of
profound hemodynamic deterioration, heparinization, cannulation,
and cardiopulmonary bypass were then possible. The skull pedes-
Figure 1. Diagram showing the principle of power delivery to the
Jarvik 2000 heart.
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tal was implanted by an experienced cochlear implant surgeon
(A.F.). A cork bore–type instrument the same diameter as the
percutaneous part of the titanium pedestal was used to tunnel
through the skin to the periosteum at the chosen site. An appro-
priately sized skin defect was thereby created. A C-shaped incision
was then made around this on the basis of the occipital arterial
supply, and a full-thickness flap was raised down to the periostium
(Figure 2, A). The periostium was elevated beneath the skin flap,
and a template was used to define the position of the bone screws.
Any skull irregularity was burred off to give a flat surface. A dental
drill was used to penetrate the external table before inserting the
self-tapping screws.
Meanwhile, the left thoracotomy was performed through the
sixth intercostal space to expose the apex of the left ventricle and
the descending thoracic aorta. The Jarvik 2000 heart and power
cable were brought into the surgical field, and the incisions were
made on the shoulder and neck to convey the 3-pin connector and
power cable to the skull-pedestal site. This was achieved by
inserting the 3-pin connector within the end of an intercostal drain.
The drain was withdrawn out of the chest and through the neck to
the scalp. The 3-pin connector was then inserted through the
titanium pedestal (Figure 3, A). This was then implanted firmly
onto the external table by using 7- or 8-mm bone screws (Figure 3,
B). Bone dust from flattening of the external table or the screw hole
was used to promote osseointegration. The postauricular skin flap
was repositioned with the percutaneous pedestal through the
punched-out defect. The scalp and skin incisions were then closed
securely. The external power cable was attached to the skull
pedestal, and with the Jarvik 2000 heart in a bowl of saline, the
power was switched on to test the circuit.
A side clamp was then applied to the descending thoracic aorta,
to which a 16-mm Dacron graft was anastomosed. Systemic hep-
arinization was then undertaken, and the left femoral artery and
vein were cannulated for cardiopulmonary bypass.
The pericardium was opened widely anterior to the left phrenic
nerve. The apex of the globular left ventricle was identified and
cored, and the Jarvik 2000 restraining cuff was sewn into position.
The Jarvik 2000 heart was then inserted through the cuff and fixed
in position with circumferential tapes. The Dacron graft attached to
the pump was trimmed to length and anastomosed to the graft on
the descending aorta. Meanwhile, the heart was defibrillated and
filled to dispel air. When the whole system was thoroughly
deaired, the pump was switched on, and the patient was weaned
from cardiopulmonary bypass.
Postoperative Care
The percutaneous pedestal required very little maintenance.4 On
the first postoperative day, the dressings were removed, and the
site was cleaned and kept dry. The external cable was discon-
nected, and blood clot or debris was cleaned from the surfaces. The
patients tolerated discontinuation of pump flow for up to 5 min-
utes, with a functional aortic regurgitation flow of 800 to 1000
mL/min. For the first 3 months during the process of osseointe-
gration, every attempt was made not to apply weight or tension to
the pedestal.
Results
During the learning curve for the procedure, implantation of
the power system took between 50 and 80 minutes. For the
Figure 2. Passage of the power cable from the second intercostal space to the postauricular pedestal: A, skin
incision and external connector; B, plain radiograph showing the power cable passing in a gentle curve through
the neck.
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first patient, access to both sides of the neck to zigzag the
cable proved difficult, and profound hemodynamic deterio-
ration occurred when the left lung was collapsed. This
required early heparinization and cardiopulmonary bypass
before the system was finished. During the second postop-
erative week, an acute bend in the cable began to erode
through one of the neck incisions. This required revision
into a deeper pocket by using local anesthetic and a
regional nerve block. After this, all wounds healed satis-
factorily, and there has been no infection over 12 months.
The patient lived at home in New York Heart Association
class I for 10 months and has now survived 1 year after
implantation.
In the second (112 kg) patient the implant seemed un-
eventful, and he initially recovered from anesthesia and
moved all limbs to command. However, severe coagulopa-
thy resulted in excessive blood transfusion with pulmonary
hypertension and the need for prolonged sedation and pos-
itive-pressure ventilation. Ten days after the operation, he
was anticoagulated with warfarin, but on discontinuing se-
dation, it was apparent that there was right-sided weakness.
A CT scan revealed a subdural hemorrhage adjacent to the
site of the pedestal (Figure 6). Craniotomy was performed,
and the pedestal was detached and repositioned in a subcu-
taneous pocket. Warfarin was discontinued. The site healed
well, but because of his size and neurologic impairment, it
proved difficult to wean him from the ventilator. The com-
bination of positive-pressure ventilation and pulmonary hy-
pertension exacerbated tricuspid regurgitation and right
heart failure. Although the pump continued to function
Figure 3. Components of the percutaneous system: A, 3-pin connector and titanium pedestal; B, pedestal screwed
into the skull; C, healing pedestal with external connector.
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satisfactorily without anticoagulation, the patient died 3
months after implantation.
In patients 3 and 4 the postauricular pedestal healed well
and remains free from infection 4 weeks and 4 months later.
The patients were discharged home 3 weeks after the im-
plantation.
The system is user friendly in the outpatient setting. The
patients are able to shower and wash the hair normally. The
pedestal site is checked and cleaned thoroughly by the
LVAD nurse on outpatient visits. When the hair regrows,
the external system is virtually invisible, passing from be-
hind the ear and then under the shirt or jacket. The system
is robust, and all external components can be replaced. Our
first patient carries both controller and battery in a shoulder
bag. He has carried his system overseas by air for a vaca-
tion. On one occasion, a thief snatched the bag outside a
supermarket. The connecting cable was avulsed from the
pedestal and activated the alarm. This caused the thief to
drop the bag, after which the cable was reconnected. On
another occasion, the controller and battery were dropped
onto a hard surface, which damaged the cable connection.
Again, he was able to exchange the cable and restarted the
pump 20 minutes later without adverse effects.
Discussion
The pusher-plate LVADs are large space-occupying foreign
bodies with a direct connection to the skin through the
driveline. Now patients undergoing LVAD implantation are
more frequently released into the community, and the inci-
dence of late infective complications is prohibitive. Positive
driveline cultures have been recorded in 50% of patients
successfully bridged to transplantation, with obvious clini-
cal infection in 30%.7,8 Currently, about 30% of patients are
ultimately rejected for transplantation because of infection,
and 29% of those with major driveline problems die while
waiting for a donor organ.9 Staphylococcal organisms are
responsible for the majority of percutaneous site infections.
Disseminated Candida species infection has been described
in 28% of patients undergoing Thermo Cardiosystems
HeartMate LVAD implantation (Thermo Cardiosystems,
Inc, Woburn, Mass) by 3 months after implantation and in
45% by 9 months.10 This appears to be due to progressive
defects in T-cell immunity. Although infection may be
related to the patient’s overall clinical condition, the thick,
stiff driveline attached to the bulky mobile LVAD and
penetrating mobile skin contributes to the risk. Both local-
ized and ascending driveline infections are usually preceded
by nonhealing of the exit site, where the rigid cable moves
with the patient’s activity. Infection generally leads to re-
hospitalization, septic embolism, and reoperations, includ-
ing revision of the percutaneous driveline or removal or
exchange of the infected LVAD. These problems have a
negative effect on quality of life and cost of LVAD treat-
ment. The Jarvik 2000 power line is of much smaller caliber
and is not subject to the same stress as with pusher-plate
cables. It is likely that these improvements alone will lead to
fewer infective complications. Only 2 of 10 bridge-to-trans-
plantation patients in the Texas Heart Institute had superfi-
cial skin infection, and this did not alter their clinical course.
Bone-anchored implants that penetrate the epithelium
have been successfully used for hearing aids and for the
attachment of cosmetic prostheses in auricular malforma-
Figure 4. The controller and portable battery (combined weight <1 kg).
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tions.4,11 When the soft tissues adhere tightly to the titanium
stem, the risk of cutaneous bacteria reaching the pedestal
base and causing infection is small. The biologic acceptance
of bone-anchored foreign-body implants is influenced by
many factors, including bone density, fixing screw, host-
tissue reaction, and biocompatibility of the implant materi-
al.12 Osseointegration is the direct structural and functional
connection between living bone and the surface of the
load-carrying implant. In cochlear implants with a percuta-
neous button screwed to the skull, there is freedom from
infection of greater than 90% at 10 years.11 Many patients
have had an implant without infection for longer than 20
years. Consequently, the chances of infection reaching the
Jarvik 2000 heart through the cable are virtually nil.
Our early clinical experience is encouraging. The pedes-
tal and connector are only a little more obtrusive than an
old-fashioned hearing aid. The patient cannot hear or feel
the Jarvik 2000 heart within the chest, and the power system
allows normal life in the community. Our implant learning
curve has been important and allowed others to begin using
the system without complications. We soon abandoned the
zigzag method, which was time consuming, difficult to keep
sterile, and unnecessary. The gentle curve of the cable with
only one incision between the thoracic exit and the pedestal
is simpler and safe.
Penetration of the inner table of the skull in the second
patient was an avoidable complication. Surgical exploration
showed a single shallow drill hole that would not have
resulted in significant bleeding in the absence of coagulopa-
thy or anticoagulation. We responded to this complication
by changing the type of drill used and carefully measuring
the thickness of the skull by means of CT scanning and
having a variety of different-length self-tapping titanium
screws available. Alternative bone-anchoring points, such
as the sternum, a rib, or the iliac crest site, may also be
feasible, but the depth of subcutaneous fat is unpredictable
in these areas and may undermine the benefit of the scalp
site.
For permanent implants, the ability of the patient to
change the external system is a distinct advantage. Discon-
tinuation of the power supply for up to 30 minutes has been
tolerated, and the degree of functional aortic regurgitation
(retrogradely through the vascular graft) seems to be less
than for other devices. These patients already had significant
improvement in left ventricular function (increase in myo-
cardial oxygen consumption from 5.7 mL  min–1  kg–1
preoperatively to 12.0 mL  min–1  kg–1 in patient 1).
Significantly, there was no thromboembolism on restoration
of pump flow.
In summary, the clinical experience to 1 year echos our
freedom from infection in the laboratory. Postauricular
power delivery is user friendly in the outpatient setting, and
to date, we have had no sepsis. Permanent mechanical
circulatory support is feasible only with a mechanically
reliable pump and an acceptably low risk of infection. The
Jarvik 2000 heart with postauricular power delivery is
promising in both respects.
Roger Grey, FRCS, and Stephen Watt-Smith, FRCS, pro-
vided invaluable advice regarding the surgical aspects of pedestal
implantation. Patients 3 and 4 were operated on at the Heart
Hospital, London, United Kingdom. We greatly appreciate the
support provided by this institution.
Figure 5. The Jarvik 2000 heart and power cable in patient 1. The
cable takes a zigzag path through the neck to prevent tension in
the wires.
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Figure 6. A, CT scan of the brain showing a subcutaneous hematoma adjacent to the pedestal. B, Plain chest
radiograph showing the pump in the apex of the left ventricle.
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